Introduction
============

The placenta is a vital organ that mediates maternal-fetal exchange of nutrients and waste ([@b1-mmr-22-04-3482]). Placental development is accompanied by extensive angiogenesis, particularly in the labyrinth, the key site of fetomaternal interaction that contains both fetal and maternal blood vessels ([@b2-mmr-22-04-3482]). In mice, the labyrinthine vasculature elongates and expands to meet the needs of the growing fetus from embryonic day (E)14.5 until the end of gestation ([@b3-mmr-22-04-3482],[@b4-mmr-22-04-3482]). The initial stages of angiogenesis result in leaky, poorly perfused and easily ruptured vessels ([@b5-mmr-22-04-3482]). The developing network is repeatedly pruned and remodeled via the fusion and regression of existing vessels, until an extensive and highly-branched vascular tree consisting of blood vessels of different diameters and functions is established ([@b6-mmr-22-04-3482],[@b7-mmr-22-04-3482]). Additionally, capillary extension occurs, cell junctions are tightened and vascular perfusion becomes regulated ([@b8-mmr-22-04-3482],[@b9-mmr-22-04-3482]).

Progranulin (PGRN) is a multifunctional growth factor predominantly expressed by endothelial cells ([@b10-mmr-22-04-3482]). It serves a critical role in inflammatory processes ([@b11-mmr-22-04-3482],[@b12-mmr-22-04-3482]) and angiogenesis ([@b13-mmr-22-04-3482]). High levels of PGRN have been observed at the sites of wounds and the placenta, where angiogenesis occurs ([@b10-mmr-22-04-3482],[@b14-mmr-22-04-3482],[@b15-mmr-22-04-3482]). In human breast cancer cells, PGRN is associated with the promotion of cell proliferation and invasion ([@b16-mmr-22-04-3482]). Furthermore, it is involved in and mediates angiogenesis by directly stimulating vascular endothelial growth factor expression ([@b17-mmr-22-04-3482]). An elevated expression of the *PGRN* gene has been detected in uterine glandular epithelial cells ([@b18-mmr-22-04-3482]). It has also been detected in the original mesenchyme on the proliferating layer around the glands ([@b18-mmr-22-04-3482]). The extensive expression of PGRN is detected in villous trophoblast cells, especially syncytiotrophoblast cells ([@b19-mmr-22-04-3482]). PGRN can stimulate the cell proliferation of BeWo cells, indicating a growth-stimulating effect during the development of the placenta ([@b19-mmr-22-04-3482]). Furthermore, PGRN is a key factor in blastocyst hatching, adhesion and outgrowth ([@b20-mmr-22-04-3482]). The process of mouse blastocyst formation is delayed when PGRN expression is inhibited ([@b21-mmr-22-04-3482]). Previous studies have suggested that dysregulated PGRN expression in human placentas is associated with pregnancy-related diseases, such as pre-eclampsia (PE) and fetal growth restriction (FGR) ([@b22-mmr-22-04-3482],[@b23-mmr-22-04-3482]). Insufficient trophoblast invasion, abnormal uterine spiral artery remodeling and placental angiogenesis disorders are identified in the pathophysiology of PE ([@b24-mmr-22-04-3482],[@b25-mmr-22-04-3482]). Proteomics studies have revealed an increasing trend of PGRN expression levels in maternal plasma from the first to the third trimester during pregnancy, but after delivery, it decreases to pre-pregnancy levels ([@b26-mmr-22-04-3482]). This fluctuation may be associated with placental secretion ([@b27-mmr-22-04-3482]). However, although PGRN has been linked to blastocyst formation in reproductive development and PE pathology in several studies ([@b17-mmr-22-04-3482],[@b20-mmr-22-04-3482]--[@b23-mmr-22-04-3482]), its specific role in the development of placental blood vessels, particularly in the placental labyrinth, remains to be elucidated.

In the present study, *PGRN* gene knockout mice (*PGRN*^−/−^) were used to examine the role of PGRN in placental blood vessel development. The observed indices included placental size, structure, vascularization biomarkers, such as the vascular smooth muscle cell marker α smooth muscle actin (SMA) ([@b28-mmr-22-04-3482]), the vascular endothelial cell marker platelet endothelial cell adhesion molecule, also known as CD31 ([@b29-mmr-22-04-3482]), and endothelial nitric oxide synthase (eNOS) ([@b30-mmr-22-04-3482]), as well as pup bodyweights.

Materials and methods
=====================

### Mouse models

The animal experiments were approved by the Biomedical Ethics Committee of Chongqing Medical University and the Animal Care Committee of Chongqing Medical University (approval no. 2016-41; Chongqing, China). A total of 64 mice were used (ratio of male to female, \~0.23; weight, 19--24 g). The *PGRN*^−/−^ mice (C57BL/6 background) were purchased from the Jackson Laboratory for Genomic Medicine by Dr Ju Cao at Chongqing Medical University ([@b12-mmr-22-04-3482],[@b31-mmr-22-04-3482]). Sex- and age-matched C57BL/6 mice (C57) were purchased from the Laboratory Animal Center of Chongqing Medical University (Chongqing, China) and used as controls. Mice were kept in specific pathogen-free facilities in a 12-h light/dark cycle with free access to sterilized food and water. The indoor temperature was 20--26°C (daily temperature difference ≤4°C) and the relative humidity was 40--70%. The present study was conducted when the mice were 8--12 weeks old. After 4 days of acclimation, female mice in estrous were mated with males of the same strain (1--2 females:1 male; *PGRN*^−/−^ mated with *PGRN*^−/−^; C57 mated with C57). The females were inspected the following morning. The day a copulatory plug was found was designated as E0.5. The female mice were sacrificed humanely under anesthesia on E6.5, E14.5 and E17.5. The placentas and embryos were removed, weighed and stored at −80°C or embedded in wax, according to the protocols described subsequently. It was ensured that animals were treated with kindness and with as little pain as possible. After the materials were collected, the mice were sacrificed by anesthesia with 1% pentobarbital sodium (30--45 mg/kg) and asphyxiation with 20--30% cage volume/min CO~2~ until the concentration of CO~2~ reached 99%. Euthanasia was confirmed by the observations that the mouse had no heartbeat, had stopped breathing and the pupil of the animal was dilated.

### Histology and H&E staining

Placentas were dissected, fixed with 4% paraformaldehyde overnight at 4°C and then washed with PBS. For the paraffin block preparation, washed tissues were serially dehydrated with 75, 85, 95, 100 and 100% ethanol, soaked in xylene and then embedded in preheated soft wax at 60°C and preheated paraffin at 80°C, respectively. Paraffin sections (5-µm thick) were de-waxed in xylene, rehydrated with 100, 100, 95, 85 and 75% ethanol series, and stained with H&E at room temperature. The sections were first stained with undiluted hematoxylin for 3--8 min, washed with tap water and then differentiated with 1% hydrochloric acid alcohol for 5--10 sec, washed with tap water and then returned the nucleus from red or pink to blue with 0.6% ammonia water and then rinsed with running water. Following nuclear staining, the sections were placed in eosin staining solution for 1--3 min for cytoplasmic staining. The central sections of the placentas were analyzed for all experiments. A total of 3 wild-type (WT) and 3 *PGRN*^−/−^ placentas were examined at each of the collection points (E6.5, E14.5 and E17.5, respectively). Sections were observed using a Olympus IX81 upright light microscope, and images were catured with Olympus CellSens Standard Software (both Olympus Corporation) and analyzed via ImageJ software v 1.8.0 (National Institutes of Health).

### Immunohistochemistry and immunofluorescence

Paraffin sections (5-µm thick) were de-waxed with xylene and rehydrated with 100, 100, 95, 85 and 75% ethanol series, then microwaved in 92--98°C for 15 min for antigen retrieval. Following cooling, the sections were washed with PBS and blocked with 10% H~2~O~2~ for 10 min at room temperature, followed by 5% goat serum (cat. no. SP-9001/SP-9002; SPlink Detection kits, Biotin-Streptavidin HRP Detection Systems; OriGene Technologies, Inc.) for blocking at 37°C for 30 min. The sections were then incubated with PGRN (cat. no. ab187070; dilution, 1:200), CD31 (cat. no. ab9498; dilution, 1:500), eNOS (cat. no. ab76198; dilution, 1:500; all Abcam) antibodies, in 1% BSA (cat. no. ST023; Beyotime Institute of Biotechnology) overnight at 4°C. Subsequently, the sections were kept at room temperature for 30 min, washed with PBS and incubated with biotin-conjugated homologous secondary antibodies, namely non-diluted biotinylated goat anti-rabbit or anti-mouse IgG polymer working solution (cat. no. SP-9001/SP-9002; SPlink Detection kits, Biotin-Streptavidin HRP Detection Systems; OriGene Technologies, Inc.) at 37°C for 30 min. Following washing with PBS three times, the sections were incubated with horseradish peroxidase-conjugated streptavidin for 30 min at 37°C. Finally, the sections were washed three times with PBS and subjected to diaminobenzidine staining for the immunohistochemical tests of PGRN, CD31 and eNOS at room temperature. Images were captured using an Olympus IX81 upright light microscope, and analyzed via Olympus CellSens Standard Software (both Olympus Corporation).

In the SMA immunofluorescence assay, the steps before incubation with the primary antibody were the same as for immunohistochemistry and the subsequent immunofluorescence tests were performed in the dark. The sections were first washed three times with PBS following overnight primary antibody incubation in 4°C by anti-α smooth muscle actin (SMA; 1:200; cat. no. ab7817; Abcam) and were then incubated with the FITC-labeled goat anti-mouse secondary antibody (1:200; cat. no. IF-0051; Beijing Dingguo Changsheng Biotechnology Co., Ltd.) for 1 h at 37°C. The sections were then washed three times with PBS, followed by a 2-min incubation with DAPI (1 µg/µl in 1% BSA in PBS) at room temperature. Coverslips were mounted with the washed sections and anti-fluorescence quenching sealant was applied. Images were acquired using an Olympus IX81 upright fluorescence microscope and analyzed via Olympus CellSens Standard Software (Olympus Corporation).

### Western blot analysis

A total of three mice from each group were used in this experiment. Mice placentas were homogenized and sonicated in 99% RIPA lysis buffer (cat. no. P0013B; Beyotime Institute of Biotechnology) and 1% phenylmethanesulfonyl fluoride (cat. no. PMSF ST506; Beyotime Institute of Biotechnology) on ice and then centrifuged at 15,777 × g for 15 min at 4°C. Samples remained on ice and the protein concentrations were determined using a BCA protein assay kit (cat. no. P0010S; Beyotime Institute of Biotechnology). Next, 2 µg/µl tissue sample, loading buffer (cat. no. 1610747; Bio-Rad Laboratories, Inc.) and lysis buffer (99% RIPA lysis buffer + 1% PMSF) were mixed in proportion and boiled for 10 min, followed by the addition of 10 µl dithiothreitol. Proteins were loaded (20 µg per lane) separated using 10 and 7% SDS-PAGE and transferred onto a nitrocellulose membrane. The membrane was blocked with 5% skimmed milk/PBS for 1 h at room temperature, followed by incubation with the corresponding primary antibodies overnight at 4°C. Following three washes with PBS, the membranes were incubated with a specific horseradish peroxidase (HRP)-conjugated goat anti-rabbit/mouse IgG secondary antibody (1:5,000; cat. no. SH-0031/0011; Beijing Dingguo Changsheng Biotechnology Co., Ltd.) for 1 h at room temperature, washed with PBS three times and then incubated with Immobilon Western Horseradish Peroxidase (Merck KGaA). Western blots/arrays were visualized at room temperature using enhanced chemiluminescence western blotting reagents (cat. no. RPN2109; Cytiva) and a Bio-Rad ChemiDoc MP Imaging system. Images were analyzed via Image Lab v4.0 (Bio-Rad Laboratories, Inc.). The primary antibodies used were: PGRN (cat. no. ab187070; dilution, 1:200), CD31 (1:500; cat. no. ab9498), SMA (cat. no. ab7817; dilution, 1:200) and eNOS (cat. no. ab76198; dilution, 1:1,000; all from Abcam). Mouse monoclonal β-actin (Beijing Dingguo Changsheng Biotechnology Co., Ltd.) was used as an internal control.

### Histomorphometric measurements

For histomorphometric measurements, three sections per placenta taken at 100-µm intervals from the central region near the site of umbilical cord attachment were analyzed. The areas and diameters were measured using ImageJ software v1.8.0 (National Institutes of Health).

### Statistical analysis

Data are presented as the mean of ≥6 independent repeats. All data are presented as mean ± SEM. Statistical significance was calculated using an unpaired Student\'s t-test or Welch\'s t-test. Weight data were analyzed using a Mann-Whitney U test. GraphPad Prism v5.0 (GraphPad Software, Inc.) was used for all statistical analysis including the Kaplan-Meier plot of survival analysis using the log-rank (Mantel-Cox) and Gehan-Breslow-Wilcoxon tests. \*P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Lower PGRN expression in PGRN^−/−^ placentas

Immunoh istochemical analysis of mouse embryos at E6.5 (after implantation was completed) revealed that PGRN was present around the embryos ([Fig. 1Ab and d](#f1-mmr-22-04-3482){ref-type="fig"}) in WT mice. However, its expression was almost undetectable in *PGRN*^−/−^ mice ([Fig. 1Aa and c](#f1-mmr-22-04-3482){ref-type="fig"}). Immunohistochemistry revealed high levels of PGRN on E14.5 in the WT mice compared with in the *PGRN*^−/−^ mice, particularly in the maternal decidua and junctional zone, and partly in the labyrinthine layer, where the process of decidual transformation and fetal neovascularization is accompanied by extensive angiogenesis ([@b32-mmr-22-04-3482]--[@b35-mmr-22-04-3482]) ([Fig. 1B](#f1-mmr-22-04-3482){ref-type="fig"}). On E17.5, PGRN was most easily observed in the WT maternal decidua, followed by the labyrinthine layer ([Fig. 1Cb, d and f](#f1-mmr-22-04-3482){ref-type="fig"}), while it was less expressed in the *PGRN*^−/−^ maternal decidua and labyrinthine layer ([Fig. 1Ca, c and e](#f1-mmr-22-04-3482){ref-type="fig"}). Additionally, western blot analysis demonstrated that PGRN expression was significantly lower in *PGRN*^−/−^ placentas on E14.5 and E17.5 ([Fig. 1D](#f1-mmr-22-04-3482){ref-type="fig"}) when compared with the WT placentas.

### Smaller placentas in PGRN^−/−^ mice

The embryos of *PGRN*^−/−^ and WT C57 mice were visible, as were the decidual cells around them ([Fig. 2A](#f2-mmr-22-04-3482){ref-type="fig"}). *PGRN*^−/−^ placentas exhibited normal structure of the three compartments (maternal decidua, junctional zone and labyrinthine layer). However, the total area of the *PGRN*^−/−^ placentas was significantly smaller compared with that of the WT placentas, and the area of the labyrinth zone was reduced on E14.5 ([Fig. 2Ba and b, and 2C](#f2-mmr-22-04-3482){ref-type="fig"}) and E17.5 ([Fig. 2Be and f, and 2D](#f2-mmr-22-04-3482){ref-type="fig"}). The labyrinth appeared to be more compact, with more clusters of densely packed trophoblast cells in the *PGRN*^−/−^ placenta on E14.5 and E17.5 ([Fig. 2Bc and g](#f2-mmr-22-04-3482){ref-type="fig"}), compared with the WT placenta ([Fig. 2Bd and h](#f2-mmr-22-04-3482){ref-type="fig"}). The fetal blood vessel spaces were decreased in the *PGRN*^−/−^ mice compared with the WT placenta, and the embryonic erythrocytes, which were less frequently detected, appeared to be squeezed into the narrowed vessels ([Fig. 2Bc and g](#f2-mmr-22-04-3482){ref-type="fig"}). Furthermore, the weight of the *PGRN*^−/−^ placentas was significantly lower compared with that of the WT placentas on E14.5 and E17.5 ([Fig. 2E and F](#f2-mmr-22-04-3482){ref-type="fig"}).

### Abnormal placental vascularization in PGRN^−/−^ mice

To further investigate the altered placental vascularization, western blot analysis and immunohistochemistry of CD31 expression were conducted. CD31 staining was observed in the vascular endothelial cells of WT mice, most of which resided in the labyrinth zone, while the rest was expressed in the maternal decidua on E14.5 ([Fig. 3Ab](#f3-mmr-22-04-3482){ref-type="fig"}) and E17.5 ([Fig. 3Bb](#f3-mmr-22-04-3482){ref-type="fig"}). A markedly lower amount of CD31 was observed in the labyrinthine layer of the *PGRN*^−/−^ placentas on E14.5 ([Fig. 3Aa and c](#f3-mmr-22-04-3482){ref-type="fig"}). In addition, the blood vessels in the WT placental labyrinth aligned in a polar manner from the maternal to the fetal side, while there were fewer vessels in the *PGRN*^−/−^ placental labyrinth, which were arrayed in a disorderly manner ([Fig. 3Ac and d](#f3-mmr-22-04-3482){ref-type="fig"}, and [3Bc and d](#f3-mmr-22-04-3482){ref-type="fig"}). On E14.5, the labyrinthine layer of the *PGRN*^−/−^ placentas exhibited a higher density and a considerably more disordered trophoblast cell distribution ([Fig. 3Ac](#f3-mmr-22-04-3482){ref-type="fig"}). Additionally, a higher-magnification examination of the maternal decidua revealed that the vascular endothelium was more compacted and blood vessel expansion appeared to be restricted, which led to a smaller vessel lumen in the *PGRN*^−/−^ placenta ([Fig. 3Ae](#f3-mmr-22-04-3482){ref-type="fig"}) compared with the WT placenta ([Fig. 3Af](#f3-mmr-22-04-3482){ref-type="fig"}). Smaller terminal sinusoids were observed in the *PGRN*^−/−^ placental labyrinth, compared with the WT placental labyrinth, accompanied by inordinate trophoblast cells on E14.5 ([Fig. 3Ac and d](#f3-mmr-22-04-3482){ref-type="fig"}). During the development of the normal placenta, as the chorioallantoic interface underwent more extensive branching, the trophoblast-lined sinusoid spaces became progressively smaller ([Fig. 3Bd](#f3-mmr-22-04-3482){ref-type="fig"}). However, the sinusoid spaces of the labyrinth in the *PGRN*^−/−^ placentas on E17.5 were much larger compared with those in the WT placentas ([Fig. 3Bc](#f3-mmr-22-04-3482){ref-type="fig"}). CD31 was expressed at higher levels on E17.5 than on E14.5, in the *PGRN*^−/−^ ([Fig. 3Ba and c](#f3-mmr-22-04-3482){ref-type="fig"}) and WT groups ([Fig. 3Bb and d](#f3-mmr-22-04-3482){ref-type="fig"}), especially in the labyrinthine layer. The difference in the staining density of CD31 between the two groups was more apparent on E17.5 than on E14.5. Western blot analysis revealed that CD31 expression in WT placentas was significantly higher compared with that in the *PGRN*^−/−^ placentas on E14.5 and E17.5 ([Fig. 3C](#f3-mmr-22-04-3482){ref-type="fig"}).

To gain a more detailed understanding, placental SMA was stained using immunofluorescence to examine the smooth muscles of the blood vessels. The SMA staining results demonstrated that the number of fetal red blood cells was lower in the *PGRN*^−/−^ placenta labyrinthine layer ([Fig. 4A and C](#f4-mmr-22-04-3482){ref-type="fig"}) compared with the WT placentas ([Fig. 4B and D](#f4-mmr-22-04-3482){ref-type="fig"}). A higher-magnification examination on E14.5 revealed a smaller vascular diameter, as well as less vascular distribution and fetal red blood cells in the *PGRN*^−/−^ placentas ([Fig. 4A](#f4-mmr-22-04-3482){ref-type="fig"}). In WT placentas, the fetal blood vessels were elongated and radiated uniformly from the chorionic plate to the labyrinthine layer ([Fig. 4B](#f4-mmr-22-04-3482){ref-type="fig"}). On E17.5, extensive branching of the fetal capillaries was observed in the WT placentas. In accordance with the observations on E14.5, the vascular smooth muscles of the WT placentas appeared elongated in long, straight segments and ran parallel to each other toward the decidua ([Fig. 4D](#f4-mmr-22-04-3482){ref-type="fig"}). By contrast, the vascular smooth muscles in the *PGRN*^−/−^ placentas were randomly aligned, abnormally branched and irregular in diameter ([Fig. 4C](#f4-mmr-22-04-3482){ref-type="fig"}). Furthermore, it was observed that the fetal blood vessels were dilated, the smooth muscle cells were separated from the trophoblast and branching of the fetal capillaries was defective in the *PGRN*^−/−^ placentas ([Fig. 4C](#f4-mmr-22-04-3482){ref-type="fig"}). Western blot analysis demonstrated that the WT placentas exhibited significantly higher protein expression levels of SMA compared with the *PGRN*^−/−^ placentas on both E14.5 and E17.5 ([Fig. 4E and F](#f4-mmr-22-04-3482){ref-type="fig"}).

### Decreased expression of vasodilation factors in PGRN^−/−^ placentas

eNOS was detected in the labyrinthine layer of *PGRN*^−/−^ and WT mice on both E14.5 and E17.5 ([Fig. 5Aa and b, and Ba and b](#f5-mmr-22-04-3482){ref-type="fig"}). However, it was only observed in the junctional zone on E14.5, but not on E17.5 ([Fig. 5Aa and b, and Ba and b](#f5-mmr-22-04-3482){ref-type="fig"}). The expression levels of eNOS in the labyrinthine layer were much higher in WT mice compared with in *PGRN*^−/−^ mice on E14.5 and E17.5 ([Fig. 5Ac and d](#f5-mmr-22-04-3482){ref-type="fig"}, and [Bc and d](#f5-mmr-22-04-3482){ref-type="fig"}). Western blot analysis demonstrated that eNOS expression in the WT group was higher than that in the *PGRN*^−/−^ group on E14.5 and E17.5 ([Fig. 5C](#f5-mmr-22-04-3482){ref-type="fig"}).

### Growth retardation in newborn PGRN^−/−^ pups

*PGRN*^−/−^ mice were viable and fertile ([Fig. 6A](#f6-mmr-22-04-3482){ref-type="fig"}). The number of pups produced was not affected by the parental genotype ([Fig. 6A](#f6-mmr-22-04-3482){ref-type="fig"}). No significant difference was observed between the weights of the embryos of the two groups on E14.5 and E17.5 ([Fig. 2E and F](#f2-mmr-22-04-3482){ref-type="fig"}). However, the body weights of the newborn pups of the *PGRN*^−/-^ mice were significantly lower compared with the WT pups ([Fig. 6B](#f6-mmr-22-04-3482){ref-type="fig"}). Furthermore, survival analysis demonstrated that the mortality of *PGRN*^−/−^ pups was significantly higher than that of WT controls ([Fig. 6C](#f6-mmr-22-04-3482){ref-type="fig"}).

Discussion
==========

Previous studies have demonstrated that PGRN serves a role in vascular development ([@b36-mmr-22-04-3482],[@b37-mmr-22-04-3482]). Furthermore, studies have suggested that PGRN expression in the human placenta is closely associated with certain pregnancy-related diseases, such as PE and fetal FGR ([@b22-mmr-22-04-3482],[@b23-mmr-22-04-3482]). The pathogenesis of PE and FGR is complex and cannot be explained by a single change, including the lack of trophoblast invasion and abnormal placental angiogenesis, as well as for several other reasons such as persistent placental hypoxia and the release of numerous mediators into the maternal circulation ([@b24-mmr-22-04-3482],[@b25-mmr-22-04-3482]). The significant increase in serum PGRN levels in women with PE ([@b22-mmr-22-04-3482]) suggests that the incidence of PE is uncertain, due to insufficient PGRN, which may be due to other reasons that lead to insufficient placental angiogenesis in PE and FGR. In order to promote angiogenesis, PGRN in the body is elevated but the angiogenesis outcome of PE and FGR cannot be completely rectified. The specific association and underlying mechanism require further research. In the present study, a *PGRN* knockout mouse model was used to determine whether PGRN served a role in the development of placental vasculature, particularly in the labyrinth.

Abnormal PGRN expression in endothelial cells influences angiogenesis *in vivo* ([@b38-mmr-22-04-3482]). Studies have reported high levels of PGRN expression in the placenta of minks and mice ([@b14-mmr-22-04-3482],[@b39-mmr-22-04-3482]). In adults, rapidly renewed epithelial cells, such as corneal or intestinal epithelial cells in deep crypts, express *PGRN* genes at high levels, while most epithelial cells in the resting state of mitosis, such as the epithelial cells of the lungs or renal tubules, have relatively low expression levels ([@b18-mmr-22-04-3482]). Additionally, the findings of the present study demonstrated PGRN expression in the placentas of WT mice, which reflected the expression and distribution of PGRN in mouse placentas under normal conditions. It has been reported that PGRN can increase the capillary size and number when added to rodent dermal wounds ([@b10-mmr-22-04-3482]). Another study reported that PGRN influences vasculogenesis by regulating vascular permeability in the brain ([@b40-mmr-22-04-3482]). The data of the present study revealed that the knockout of the *PGRN* gene in a mouse model resulted in placental blood vessels of a smaller diameter and reduced distribution. A previous study demonstrated that PGRN affects angiogenic behavior *in vitro* and *in vivo* ([@b41-mmr-22-04-3482]). Other studies examined the effect of PGRN in isolated superior rat mesenteric artery rings and revealed that it is involved in the regulation of vascular tone by regulating eNOS and smooth muscle ([@b36-mmr-22-04-3482],[@b42-mmr-22-04-3482]). Another study suggested that eNOS contributes to changes in uterine placental blood vessels and increases in uterine artery blood flow during pregnancy ([@b30-mmr-22-04-3482]). Furthermore, PGRN reportedly upregulates the Akt/eNOS phosphorylation level in human umbilical vein endothelial cells ([@b37-mmr-22-04-3482],[@b43-mmr-22-04-3482]). The present study demonstrated that the expression of eNOS and SMA in *PGRN*^−/−^ placentas was lower compared with that in WT placentas. In the experimental results of the present study, it could be observed under a high magnification that *PGRN*^−/−^ genotype maternal decidual vascular endothelial cells were denser, blood vessel walls were thicker and the placental vascular lumen diameter was reduced compared with WT placental cells. These phenomena suggested that, when *PGRN* is knocked out, the defective expression of eNOS in the mouse placenta may cause vascular remodeling disorders. Therefore, the present findings, combined with those of previous studies, demonstrated that PGRN regulates placental angiogenesis.

The maternal-fetal interface is mainly made up of the maternal decidua, the junctional zone and the labyrinthine layer, which undergo extensive angiogenesis during pregnancy ([@b35-mmr-22-04-3482]). The labyrinthine layer is a widely vascularized tissue and abnormal vascular formation can lead to aberrant placental development ([@b32-mmr-22-04-3482],[@b35-mmr-22-04-3482]). Previous studies have demonstrated that follicle stimulating hormone receptor, TEK receptor tyrosine kinase, vascular cell adhesion molecule-1, ESX homeobox 1 (Esx1), connexin 45, platelet-derived growth factor B/β-receptor and aryl hydrocarbon receptor nuclear translocator (ARNT) are important genes during vascular development, whose knockout results in a defective labyrinth ([@b44-mmr-22-04-3482]--[@b49-mmr-22-04-3482]). Additional studies have reported genes, such as the translocon-associated protein subunit γ, Esx1, ARNT and retinoid X receptors, to be associated with normal labyrinth development, and knocking out any one of them can lead to a narrowed labyrinth, abnormal placental development, fetal growth retardation or even fetal death ([@b39-mmr-22-04-3482],[@b46-mmr-22-04-3482],[@b49-mmr-22-04-3482],[@b50-mmr-22-04-3482]). Additionally, a narrowed labyrinth and distributed dysplastic fetal capillaries in *PGRN*^−/−^ mice were observed in the present study. These findings suggested that insufficient PGRN leads to abnormal blood vessel development and can result in a defective labyrinth and insufficient placental development. When comparing the placenta weights of *PGRN*^−/−^ and WT mice on E14.5 and E17.5, the placenta weight of *PGRN*^−/−^ mice was significantly lower compared with that of WT normal mouse placentas. This result demonstrated that the absence of PGRN expression in mice can delay placental development. The difference in chorionic artery branching between the normal and FGR placentas is caused by the different placenta sizes ([@b51-mmr-22-04-3482]). FGR placentas show microvascular degeneration and extreme vascular deficiencies in the surrounding area, and these features are likely to limit the placental ability to meet fetal nutritional needs in late pregnancy ([@b51-mmr-22-04-3482]). The data from the present study revealed that the weight of the *PGRN*^−/−^ placentas and newborn pups, and the survival rate of *PGRN*^−/−^ pups, were significantly lower compared with those of mice in the WT group. Therefore, insufficient PGRN may affect pup weight and survival rate as a result of the disordered labyrinth and abnormal placental function.

In the present study, it was revealed that knocking out *PGRN* led to a smaller diameter and less distribution of the blood vessels in the placenta and affected the body weight of the pups following their birth. This result suggested that the bodyweight of the pups was not directly affected by the underdeveloped placenta. However, the *PGRN*^−/−^ pup body weight increased at a significantly slower rate compared with WT pups, which might be due to two possible reasons. First, that the underdeveloped placenta hindered the normal development of the pups ([@b39-mmr-22-04-3482],[@b46-mmr-22-04-3482],[@b49-mmr-22-04-3482],[@b50-mmr-22-04-3482]) and second, that the *PGRN*^−/-^ gene prevented the pups from normal postnatal growth due to problems associated with angiogenesis in key organs ([@b40-mmr-22-04-3482],[@b52-mmr-22-04-3482],[@b53-mmr-22-04-3482]). Therefore, to what extent the underdeveloped placenta and the *PGRN*^−/−^ gene that the pups carry affect the growth of the pups requires further investigation.

In conclusion, the present study demonstrated that the absence of PGRN may lead to aberrant angiogenesis in the placental labyrinth, further disrupting the structure of the nutrient-waste exchange system, which may give rise to adverse pregnancy outcomes. Further analysis of *PGRN* knockout mice should be conducted to provide insights into the molecular mechanisms regulating the vasculature of the placenta. The results of the present study expanded the list of known growth factors regulating placental angiogenesis, by demonstrating that placental PGRN is essential for appropriate angiogenesis of the placenta, particularly in the labyrinth.
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![PGRN in developing embryos on E6.5 and placentas on E14.5 and E17.5. Immunohistochemistry was performed on sections of embryos on (A) E6.5, and placental tissues on (B) E14.5 and (C) E17.5. (A) Boxed areas in (a) and (b) are magnified in (c) and (d), respectively. (B and C) Boxed areas in (a) are magnified in (c) and (e). Boxed areas in (b) are magnified in (d) and (f). (D) Western blot analysis of placental tissue on E14.5 and E17.5. Scale bar, 500 µm; magnified scale bar, 50 µm. \*\*P\<0.01. PGRN, progranulin; E, embryonic day; -/-, PGRN^−/−^ mice; +/+, WT mice; WT, wild-type; EM, embryo; MD, maternal decidua; JZ, junctional zone; LB, labyrinthine layer; ACTB, β-actin.](MMR-22-04-3482-g00){#f1-mmr-22-04-3482}

![Changes in PGRN^−/−^ mouse placentas and embryos. (A) H&E staining of (a and c) PGRN^−/−^ sections and (b and d) WT (C57) embryos on E6.5. (c and d) Higher magnifications of the boxed areas in (a) and (b) show the embryos. (B) H&E staining of PGRN^−/−^ sections and WT (C57) placentas on (a-d) E14.5 and (e-h) E17.5. Higher magnifications of the boxed areas in (a), (b), (e) and (f) show the structure of the labyrinth and the red blood cells of PGRN^−/−^ and WT placentas on the maternal and fetal sides on (c and d) E14.5 and (g and h) E17.5. (C) Morphometrical analysis of sections in (Ba and b) E14.5. (D) Morphometrical analysis of sections in (Be and f) E17.5. (E) Weights of placentas and embryos from WT and PGRN^−/−^ mice on E14.5 were analyzed. (F) Weights of placentas and embryos from WT and PGRN^−/−^ mice on E17.5 were analyzed. Scale bar, 500 µm; magnified scale bar, 50 µm. \*P\<0.05, \*\*\*P\<0.001. PGRN, progranulin; H&E, hematoxylin and eosin; -/-, PGRN^−/−^ mice; +/+, WT mice; WT, wild-type; E, embryonic day; Em, embryo; MD, maternal decidua; JZ, junctional zone; LB, labyrinthine layer; frbc, fetal red blood cells; mrbc, maternal red blood cells.](MMR-22-04-3482-g01){#f2-mmr-22-04-3482}

![CD31 expression in developing placentas from PGRN^−/−^ and WT mice on E14.5 and E17.5. Immunohistochemical detection of CD31 in the serial placental sections on (A) E14.5 and (B) E17.5. (A and B) Boxed areas in (a) are magnified in panels (c) and (e). Boxed areas in (b) are magnified in panels (d) and (f). (C) Western blot analysis and quantification of the results in placentas on E14.5 and E17.5. Scale bar, 500 µm; magnified scale bar, 50 µm. \*P\<0.05. CD31, cluster of differentiation 31; PGRN, progranulin; -/-, PGRN^−/−^ mice; WT, wild-type; E, embryonic day; MD, maternal decidua; JZ, junctional zone; LB, labyrinthine layer; MBS, maternal blood sinus; FBV, fetal blood vessel; VEC, vascular endothelial cells; mrbc, maternal red blood cells; ACTB, β-actin.](MMR-22-04-3482-g02){#f3-mmr-22-04-3482}

![SMA expression in developing placentas of PGRN^−/−^ and WT mice on E14.5 and E17.5. Immunofluorescence evaluation of SMA in (A) the placentas of PGRN^−/−^ mice on E14.5, (B) the placentas of WT mice on E14.5, (C) the placentas of PGRN^−/−^ mice on E17.5 and (D) the placentas of WT mice on E17.5. Western blot analysis was performed on placental tissue on (E) E14.5 and (F) E17.5. Scale bar, 50 µm. \*P\<0.05. SMA, smooth muscle actin; -/-, PGRN^−/−^ mice; PGRN, progranulin; WT, wild-type; E, embryonic day; TGC, trophoblast giant cells; fbv, fetal blood vessels; mrbc, maternal red blood cells; frbc, fetal red blood cells; ACTB, β-actin.](MMR-22-04-3482-g03){#f4-mmr-22-04-3482}

![eNOS expression in the developing placenta is lower in PGRN^−/−^ than in WT placentas on both E14.5 and E17.5, particularly in the labyrinthine layer of the placenta. Immunohistochemistry was performed on serial placental sections from (A) E14.5 and (B) E17.5 to determine eNOS expression. (A and B) Boxed areas in (a) are magnified in (c). Boxed areas in (b) are magnified in (d). (C) Western blotting and relative gray analysis was performed on placentas on E14.5 and E17.5. Scale bar, 500 µm; magnified scale bar, 50 µm. \*\*P\<0.01. eNOS, endothelial nitric oxide synthase; -/-, PGRN^−/−^ mice; PGRN, progranulin; WT, wild-type; E, embryonic day; MD, maternal decidua; JZ, junctional zone; LB, labyrinthine layer; ACTB, β-actin.](MMR-22-04-3482-g04){#f5-mmr-22-04-3482}

![Number, weight and survival rate of newborn pups born from WT and PGRN^−/−^ parents. (A) Number of pups born from WT or PGRN^−/−^ parents. (B) Body weight of WT and PGRN^−/−^ pups following birth. The boxes indicate the 25th and 75th percentile, the bands within these boxes indicate the median values, and the ends of the bars indicate the maximum and minimum values. (C) Survival proportion between the two groups (−/- and +/+) of *PGRN*^−/−^ and WT mice 2 months after birth. \*\*P\<0.01, \*\*\*P\<0.001 vs. -/-x-/- weight in the same week. +/+, WT mice; WT, wild-type; -/-, *PGRN*^−/−^ mice; PGRN, progranulin.](MMR-22-04-3482-g05){#f6-mmr-22-04-3482}
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